Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients.
iPSC-derived neural precursors exert a neuroprotective role in immune-mediated demyelination via the secretion of LIF.
Incidence of multiple sclerosis in the United Kingdom : findings from a population-based cohort.
Sex-related factors in multiple sclerosis susceptibility and progression.
Increased axonal expression of nectin-1 in multiple sclerosis plaques.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
Increased PK11195 PET binding in the cortex of patients with MS correlates with disability.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Combining HLA-DR risk alleles and anti-Epstein-Barr virus antibody profiles to stratify multiple sclerosis risk.
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
The value of specialty pharmaceuticals - a systematic review.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
Co-enzyme Q10 and idebenone use in Friedreich's ataxia.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Acute Cryptococcal Immune Reconstitution Inflammatory Syndrome in a Patient on Natalizumab.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate

Pages